Results 111 to 120 of about 44,597 (222)

Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin‐4 Expression: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Sarcomatoid urothelial carcinoma (UC) is an extremely rare and aggressive subtype with a poor prognosis. Reports on the efficacy of enfortumab vedotin (EV) in this subtype remain limited. Case Presentation A 74‐year‐old man presented with gross hematuria and was diagnosed with metastatic sarcomatoid UC of the urinary bladder with ...
Sonin Chon, Shoichi Nagamoto, Takahisa Yamashita, Kenta Fujii, Kazuki Yokota, Kojiro Tachibana, Sachi Kitayama, Yohei Okada, Satoru Kawakami, Akihiro Yano   +9 more
wiley   +1 more source

Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low‐ and High‐Grade Papillary Urothelial Carcinoma

Cancer Medicine
Background Papillary urothelial carcinoma (transitional cell carcinoma) is one of the most common malignant tumors of the urinary tract. Urothelial carcinomas are classified into muscle‐invasive and non‐muscle‐invasive types.
Natalia Domian, Grzegorz Młynarczyk, Irena Kasacka   +2 more
doaj   +1 more source

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

Quantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang, Chung‐I Li, Rui Xin, Jijun Tang, Yan Guo   +4 more
wiley   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2885-2898, August 2026.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

When to Adjust for Multiple Testing: A Unifying Guiding Principle

Biometrical Journal, Volume 68, Issue 4, August 2026.
ABSTRACT Most original articles published in the medical literature report the results of multiple statistical tests. In a few simple cases, there is agreement on whether to adjust for the number of performed tests. For many cases encountered in practice, however, this is less clear, and the recommendations in the literature are contradictory, along ...
Sabine Hoffmann, Simon Lemster, Gary Collins, Alexander Hapfelmeier, Georg Heinze, Andreas Mayr, Matthias Schmid, Juliane C. Wilcke, Anne‐Laure Boulesteix   +8 more
wiley   +1 more source

Primary Large Cell Neuroendocrine Carcinoma of the Bladder Successfully Treated With Radical Cystectomy Alone: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Primary large‐cell neuroendocrine carcinoma of the bladder is highly invasive and has a poor prognosis. However, early curative treatment may lead to a good prognosis.
Shun Aoki, Takashi Kawahara, Yuri Nishino, Hideki Tsukada, Takayuki Hirano, Genta Iwamoto, Shusei Fusayasu, Jun‐ichi Teranishi, Kazuhide Makiyama, Hiroyuki Hayashi, Hiroji Uemura, Masatoshi Moriyama, Junichi Ohta   +12 more
wiley   +1 more source

Identification of Prognostic Genes Relevant With the Nuclear Factors of Activated T Cells Based on Transcriptomics in Oral Squamous Cell Carcinoma

Clinical and Experimental Dental Research, Volume 12, Issue 4, August 2026.
ABSTRACT Background It has previously been demonstrated that the nuclear factor of activated T cells (NFAT) is crucial for the development of tumors. Given OSCC's drug resistance and poor outcomes, identifying NFAT‐associated prognostic genes is urgent for better treatment.
Julaiti Tuerxun, Ailimaierdan Ainiwaer, Tairan Ding   +2 more
wiley   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, Volume 46, Issue 8, Page 2599-2622, August 2026.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source